Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: A prospective, randomised trial

European Journal of Endocrinology

Volumn 162, Issue 4, 2010, Pages 661-666

  Mao, Zhi Gang ^a   Zhu, Yong Hong ^b   Tang, Hai Liang ^c   Wang, Dao Yuan ^a   Zhou, Jing ^b   He, Dong Sheng ^a   Lan, Hai ^a   Luo, Bai Ning ^a   Wang, Hai Jun ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; ADRENAL CORTEX ADENOMA; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; GROWTH HORMONE RELEASE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TRANSSPHENOIDAL SURGERY; TREATMENT OUTCOME;

ACROMEGALY; ADENOMA; ADULT; ANTINEOPLASTIC AGENTS; CHI-SQUARE DISTRIBUTION; COMBINED MODALITY THERAPY; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PITUITARY NEOPLASMS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; SOMATOSTATIN;

EID: 77950324692     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0908     Document Type: Article

References (29)

1. Biermasz NR, Smit JW, Pereira AM, Frölich M, Romijn JA & Roelfsema F. Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients. Pituitary 2007 10 237-249.
2. Mestron A,Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M & Gilabert M. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). European Journal of Endocrinology 2004 151 439-446.
3. Colao A, Ferone D, Marzullo P & Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Reviews 2004 25 102-152.
4. Melmed S. Medical progress: acromegaly. New England Journal of Medicine 2006 355 2558-2573.
5. Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB &Wass JA. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clinical Endocrinology 1999 50 561-567.
6. Kreutzer J, Vance ML, Lopes MB & Laws ER Jr. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. Journal of Clinical Endocrinology and Metabolism 2001 86 4072-4077.
7. Wass JA, Turner HE & Adams CB. The importance of locating a good pituitary surgeon. Pituitary 1999 2 51-54.
8. Fahlbusch R & Buchfelder M. Transsphenoidal surgery of parasellar pituitary adenomas. Acta Neurochirurgica 1988 92 93-99.
9. Sheppard MC. Primary medical therapy for acromegaly. Clinical Endocrinology 2003 58 387-399.
10. Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D & Barkan A. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 4405-4410.
11. Abe T & Lüdecke DK. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. European Journal of Endocrinology 2001 145 137-145.
12. Colao A, Ferone D, Cappabianca P, del Basso De Caro ML, Marzullo P, Monticelli A, Alfieri A, Merola B, Calì A, de Divitiis E & Lombardi G. Effect of octreotide pretreatment on surgical outcome in acromegaly. Journal of Clinical Endocrinology and Metabolism 1997 82 3308-3314.
13. Barkan AL, Lloyd RV, Chandler WF, Hatfield MK, Gebarski SS, Kelch RP & Beitins IZ. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. Journal of Clinical Endocrinology and Metabolism 1988 67 1040-1048.
14. Biermasz NR, van Dulken H & Roelfsema F. Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls. Journal of Clinical Endocrinology and Metabolism 1999 84 3551-3555.
15. Kristof RA, Stoffel-Wagner B, Klingmüller D & Schramm J. Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study Acta Neurochirurgica 1999 141 399-405.
16. Di Chiro G & Nelson KB. The volume of the sella turcica. American Journal of Roentgenology, Radium Therapy, and Nuclear Medicine 1962 87 989-1008.
17. Plöckinger U & Quabbe HJ. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study. Acta Neurochirurgica 2005 147 485-493.
18. Lucas-Morante T, García-Uría J, Estrada J, Saucedo G, Cabello A, Alcañiz J & Barceló B. Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery. Journal of Neurosurgery 1994 81 10-14.
19. Stevenaert A & Beckers A. Presurgical octreotide: treatment in acromegaly. Metabolism 1996 45 (Suppl 1) 72-74.
20. Carlsen SM, Lund-Johansen M, Schreiner T, Aanderud S, Johannesen O, Svartberg J, Cooper JG, Hald JK, Fougner SL, Bollerslev J & Preoperative Octreotide Treatment of Acromegaly Study Group. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. Journal of Clinical Endocrinology and Metabolism 2008 93 2984-2990.
21. Ikeda H, Jokura H & Yoshimoto T. Transsphenoidal surgery and adjuvant gamma knife treatment for growth hormone-secreting pituitary adenoma. Journal of Neurosurgery 2001 95 285-291.
22. Shimon I, Cohen ZR, Ram Z & Hadani M. Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery 2001 48 1239-1245.
23. Jehle S, Reyes CM, Sundeen RE & Freda PU. Alternate day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 1588-1593.
24. Mukherjee A, Monson JP, Jonsson PJ, Trainer PJ & Shalet SM. Seeking the optimal target range for insulin-like growth factor I during the treatment of adult growth hormone disorders. Journal of Clinical Endocrinology and Metabolism 2003 88 5865-5870.
25. Puder JJ, Nilavar S, Post KD & Freda PU. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 1972-1978.
26. Swearingen B, Barker FG II, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM & Zervas NT. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism 1998 83 3419-3426.
27. Holdaway IM, Rajasoorya C & Gamble GD. Factors influencing mortality in acromegaly. Journal of Clinical Endocrinology and Metabolism 2004 89 667-674.
28. Trainer PJ. Editorial: acromegaly - consensus, what consensus? Journal of Clinical Endocrinology and Metabolism 2002 87 3534-3536.
29. Biermasz NR, Pereira AM, Frölich M, Romijin JA, Veldhuis JD & Roelfsema F. Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly. American Journal of Physiology. Endocrinology and Metabolism 2004 286 25-30.